Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss		Retained Earnings	Treasury Stock		Noncontrolling Interests in Subsidiaries
Beginning balance (in shares) at Dec. 25, 2022			34,736
Beginning balance at Dec. 25, 2022		$ (270,664)	$ 491	$ 449,829	$ (10,135)	[1]	$ 195,856	$ (922,434)	[2]	$ 15,729
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[3]	22,500					22,376			124
Other comprehensive income (loss), net of tax		1,369			1,369	[1]
Dividends on common stock		(14,663)					(14,663)
Exercise of stock options (in shares)			15
Exercise of stock options		$ 614		614
Acquisition of Company common stock (in shares)		(2,523)	(2,523)
Acquisition of Company common stock		$ (212,444)						(212,444)	[2]
Stock-based compensation expense		3,898	$ 1	3,897
Issuance of restricted stock (in shares)			197
Issuance of restricted stock		0		(4,609)				4,609	[2]
Tax effect of restricted stock awards (in shares)			(72)
Tax effect of restricted stock awards		(5,999)		(5,999)
Distributions to noncontrolling interests		(23)								(23)
Other (in shares)			3
Other		87		(46)				133	[2]
Ending balance (in shares) at Mar. 26, 2023			32,356
Ending balance at Mar. 26, 2023		$ (475,325)	$ 492	443,686	(8,766)	[1]	203,569	(1,130,136)	[2]	15,830
Beginning balance (in shares) at Dec. 31, 2023		32,500	32,488
Beginning balance at Dec. 31, 2023		$ (443,616)	$ 492	452,290	(7,803)	[4]	219,027	(1,123,098)		15,476
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[5]	14,815					14,636			179
Other comprehensive income (loss), net of tax		249			249	[4]
Dividends on common stock		(15,023)		32			(15,055)
Exercise of stock options (in shares)			18
Exercise of stock options		$ 841	$ 1	840
Acquisition of Company common stock (in shares)		0
Stock-based compensation expense		$ (370)		(370)
Issuance of restricted stock (in shares)			141
Issuance of restricted stock		0		(4,710)				4,710
Tax effect of restricted stock awards (in shares)			(45)
Tax effect of restricted stock awards		(3,192)		(3,192)
Distributions to noncontrolling interests		(222)								(222)
Other (in shares)			2
Other		$ 95		(97)				192
Ending balance (in shares) at Mar. 31, 2024		32,600	32,604
Ending balance at Mar. 31, 2024		$ (446,423)	$ 493	$ 444,793	$ (7,554)	[4]	$ 218,608	$ (1,118,196)		$ 15,433

[1] At March 26, 2023, the accumulated other comprehensive loss of $8,766 was comprised of net unrealized foreign currency translation loss of $7,586 and net unrealized loss on the interest rate swap agreements of $1,180.

[2] Acquisition of Company common stock for the three months ended March 26, 2023, includes $2,804 of transaction costs directly attributable to share repurchases, including a 1% excise tax incurred under the Inflation Reduction Act of 2022.

[3] Net income to the Company for the three months ended March 26, 2023 excludes $46 allocable to the redeemable noncontrolling interests for our joint venture arrangements.

[4] At March 31, 2024, the accumulated other comprehensive loss of $7,554 was comprised of net unrealized foreign currency translation loss of $7,912 and net unrealized gain on the interest rate swap agreements of $358.

[5] Net income to the Company for the three months ended March 31, 2024 excludes $99, respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.